mercredi 29 mars 2017

Onco Actu du 29 mars 2017

2.5 Etiologie - Gènes

Is bad luck the leading cause of cancer? [NHS Choices]

No, We Can’t Say Whether Cancer Is Mostly Bad Luck [The Atlantic]

3.1.1 Tabac - e-cigs

Nicotine e-cigarettes legalised – Expert Reaction [Science Media Centre]

3.3 Prévention - Vaccins

New study shows HPV vaccine is working to reduce rates of genital warts [The Conversation]

4. Dépistage, diagnostic et pronostic

Trial to test for Barrett’s oesophagus launches in GP surgeries across the UK [Cancer Research UK]

4.7 Dép., diag. & prono. - Col de l'utérus

Roche announces launch of cobas HPV on the cobas 6800/8800 Systems for cervical cancer screening in markets accepting the CE mark [Roche]

5. Traitements

Rogue breast tumor proteins point to potential drug therapies [WUSTL]

Novel approach can reveal better breast cancer treatments [Baylor College of Medicine]

5.12.1 Immunothérapies - partenariats

BMS seeks leg up in immuno-oncology with Parker Institute and CRI pact [FierceBiotech]

Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute Announce Collaboration to Accelerate Immuno-Oncology Research [BMS]

Bristol-Myers partners with Parker Institute, CRI on a next-gen twist on translational R&D [EndPoints]

5.2 Pharma

Revving up for new Tesaro rival, AstraZeneca nabs quick FDA review for bigger Lynparza use [FiercePharma]

To Translate Medical Science Effectively, Researchers Must Understand Commercialization [Forbes]

5.2.1 Pharma - Partenariats

AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program [AbbVie]

5.2.3 Pharma - économie

Antiva Biosciences grabs $22M as it starts precancerous lesion candidate tests [FierceBiotech]

5.4 Traitements - Economie

Patients call for halt to NICE changes [PharmaTimes]

NICE says pancreatic cancer drug is not cost effective for routine NHS use [NICE]

Final NICE no for Shire’s pancreatic cancer drug [PharmaTimes]

Tesaro won’t reveal price of its ovarian cancer drug. But it’ll likely be near $14,000 a month [MarketWatch]

FDA Approves Zejula, A Third PARP Inhibitor, As Maintenance Therapy For Some Cancers [Forbes]

5.9 AACR

Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017 [AstraZeneca]

Clovis Oncology Announces Data Presentations at AACR Annual Meeting 2017 [Clovis]

6. Lutte contre les cancers

NICE plays key role in European project to help give better care to patients with blood cancers [NICE]

Remember why we work on cancer [Nature]

6.10.1 Politiques (USA)

White House proposes new, sweeping budget cuts at NIH [STAT]

Donald Trump aims for $1.2B in NIH cuts this year [FierceBiotech]

6.11 Patients

New cancer treatments should inform patients about quality of life beyond side effects [STAT]

6.6 Publications

ORCID in Europe: Reasons to be Cheerful [ORCID]

6.9 Controverses

University of California’s CRISPR patent win in Europe likely to be challenged [STAT]